Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency

Yasuaki Anami, Wei Xiong, Xun Gui, Mi Deng Ph.D., Chengcheng Zhang, Ningyan Zhang, Zhiqiang An, Kyoji Tsuchikama

Research output: Contribution to journalArticle

20 Citations (Scopus)

Abstract

Antibody-drug conjugates (ADCs) are emerging therapeutic agents in the treatment of cancer, and various conjugation strategies and chemical linkers have been developed to efficiently construct ADCs. Despite previous extensive efforts for improving conjugation efficiency and ADC homogeneity, most ADC linkers developed to date load only single payloads. Branched linkers that can load multiple payload molecules have yet to be fully explored. It is logical to envisage that a multi-loading strategy allows for increase in drug-to-antibody ratio (DAR) with less chemical or enzymatic modification to the antibody structure compared to traditional linear linkers, leading to efficient ADC construction, minimal destabilization of the antibody structure, and enhanced ADC efficacy. Herein, we report that the branched linkers we designed can be quantitatively installed on an anti-HER2 monoclonal antibody by microbial transglutaminase (MTGase)-mediated conjugation without impairing its antigen binding affinity, enabling modular installation of payload molecules and construction of homogeneous ADCs with increased DARs (up to 8). An anti-HER2 antibody-monomethyl auristatin F conjugate constructed using our branched linkers showed greater in vitro cytotoxicity against HER2-expressing breast cancer cell lines than that consisting of linear linkers, demonstrating the effectiveness of the branched linker-based payload delivery. Our finding demonstrates that enzymatic ADC construction using branched linkers is a promising strategy, which may lead to innovative cancer therapeutics.

Original languageEnglish (US)
Pages (from-to)5635-5642
Number of pages8
JournalOrganic and Biomolecular Chemistry
Volume15
Issue number26
DOIs
StatePublished - 2017

Fingerprint

antibodies
conjugation
drugs
Antibodies
Pharmaceutical Preparations
payloads
cancer
payload delivery (STS)
Transglutaminases
Molecules
Cytotoxicity
destabilization
antigens
Anti-Idiotypic Antibodies
Neoplasms
cultured cells
breast
installing
homogeneity
affinity

ASJC Scopus subject areas

  • Biochemistry
  • Physical and Theoretical Chemistry
  • Organic Chemistry

Cite this

Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. / Anami, Yasuaki; Xiong, Wei; Gui, Xun; Deng Ph.D., Mi; Zhang, Chengcheng; Zhang, Ningyan; An, Zhiqiang; Tsuchikama, Kyoji.

In: Organic and Biomolecular Chemistry, Vol. 15, No. 26, 2017, p. 5635-5642.

Research output: Contribution to journalArticle

Anami, Yasuaki ; Xiong, Wei ; Gui, Xun ; Deng Ph.D., Mi ; Zhang, Chengcheng ; Zhang, Ningyan ; An, Zhiqiang ; Tsuchikama, Kyoji. / Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency. In: Organic and Biomolecular Chemistry. 2017 ; Vol. 15, No. 26. pp. 5635-5642.
@article{9ee2237116944da69c3582d9f89ee1e7,
title = "Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency",
abstract = "Antibody-drug conjugates (ADCs) are emerging therapeutic agents in the treatment of cancer, and various conjugation strategies and chemical linkers have been developed to efficiently construct ADCs. Despite previous extensive efforts for improving conjugation efficiency and ADC homogeneity, most ADC linkers developed to date load only single payloads. Branched linkers that can load multiple payload molecules have yet to be fully explored. It is logical to envisage that a multi-loading strategy allows for increase in drug-to-antibody ratio (DAR) with less chemical or enzymatic modification to the antibody structure compared to traditional linear linkers, leading to efficient ADC construction, minimal destabilization of the antibody structure, and enhanced ADC efficacy. Herein, we report that the branched linkers we designed can be quantitatively installed on an anti-HER2 monoclonal antibody by microbial transglutaminase (MTGase)-mediated conjugation without impairing its antigen binding affinity, enabling modular installation of payload molecules and construction of homogeneous ADCs with increased DARs (up to 8). An anti-HER2 antibody-monomethyl auristatin F conjugate constructed using our branched linkers showed greater in vitro cytotoxicity against HER2-expressing breast cancer cell lines than that consisting of linear linkers, demonstrating the effectiveness of the branched linker-based payload delivery. Our finding demonstrates that enzymatic ADC construction using branched linkers is a promising strategy, which may lead to innovative cancer therapeutics.",
author = "Yasuaki Anami and Wei Xiong and Xun Gui and {Deng Ph.D.}, Mi and Chengcheng Zhang and Ningyan Zhang and Zhiqiang An and Kyoji Tsuchikama",
year = "2017",
doi = "10.1039/c7ob01027c",
language = "English (US)",
volume = "15",
pages = "5635--5642",
journal = "Organic and Biomolecular Chemistry",
issn = "1477-0520",
publisher = "Royal Society of Chemistry",
number = "26",

}

TY - JOUR

T1 - Enzymatic conjugation using branched linkers for constructing homogeneous antibody-drug conjugates with high potency

AU - Anami, Yasuaki

AU - Xiong, Wei

AU - Gui, Xun

AU - Deng Ph.D., Mi

AU - Zhang, Chengcheng

AU - Zhang, Ningyan

AU - An, Zhiqiang

AU - Tsuchikama, Kyoji

PY - 2017

Y1 - 2017

N2 - Antibody-drug conjugates (ADCs) are emerging therapeutic agents in the treatment of cancer, and various conjugation strategies and chemical linkers have been developed to efficiently construct ADCs. Despite previous extensive efforts for improving conjugation efficiency and ADC homogeneity, most ADC linkers developed to date load only single payloads. Branched linkers that can load multiple payload molecules have yet to be fully explored. It is logical to envisage that a multi-loading strategy allows for increase in drug-to-antibody ratio (DAR) with less chemical or enzymatic modification to the antibody structure compared to traditional linear linkers, leading to efficient ADC construction, minimal destabilization of the antibody structure, and enhanced ADC efficacy. Herein, we report that the branched linkers we designed can be quantitatively installed on an anti-HER2 monoclonal antibody by microbial transglutaminase (MTGase)-mediated conjugation without impairing its antigen binding affinity, enabling modular installation of payload molecules and construction of homogeneous ADCs with increased DARs (up to 8). An anti-HER2 antibody-monomethyl auristatin F conjugate constructed using our branched linkers showed greater in vitro cytotoxicity against HER2-expressing breast cancer cell lines than that consisting of linear linkers, demonstrating the effectiveness of the branched linker-based payload delivery. Our finding demonstrates that enzymatic ADC construction using branched linkers is a promising strategy, which may lead to innovative cancer therapeutics.

AB - Antibody-drug conjugates (ADCs) are emerging therapeutic agents in the treatment of cancer, and various conjugation strategies and chemical linkers have been developed to efficiently construct ADCs. Despite previous extensive efforts for improving conjugation efficiency and ADC homogeneity, most ADC linkers developed to date load only single payloads. Branched linkers that can load multiple payload molecules have yet to be fully explored. It is logical to envisage that a multi-loading strategy allows for increase in drug-to-antibody ratio (DAR) with less chemical or enzymatic modification to the antibody structure compared to traditional linear linkers, leading to efficient ADC construction, minimal destabilization of the antibody structure, and enhanced ADC efficacy. Herein, we report that the branched linkers we designed can be quantitatively installed on an anti-HER2 monoclonal antibody by microbial transglutaminase (MTGase)-mediated conjugation without impairing its antigen binding affinity, enabling modular installation of payload molecules and construction of homogeneous ADCs with increased DARs (up to 8). An anti-HER2 antibody-monomethyl auristatin F conjugate constructed using our branched linkers showed greater in vitro cytotoxicity against HER2-expressing breast cancer cell lines than that consisting of linear linkers, demonstrating the effectiveness of the branched linker-based payload delivery. Our finding demonstrates that enzymatic ADC construction using branched linkers is a promising strategy, which may lead to innovative cancer therapeutics.

UR - http://www.scopus.com/inward/record.url?scp=85021867083&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85021867083&partnerID=8YFLogxK

U2 - 10.1039/c7ob01027c

DO - 10.1039/c7ob01027c

M3 - Article

C2 - 28649690

AN - SCOPUS:85021867083

VL - 15

SP - 5635

EP - 5642

JO - Organic and Biomolecular Chemistry

JF - Organic and Biomolecular Chemistry

SN - 1477-0520

IS - 26

ER -